CIRCUMVENT PHARMACEUTICALS, INC.
Biotech · Private
N-(tert-butyl)-hydroxylamine (CIRC827), a small-molecule therapeutic candidate for CLN1 Batten Disease
- Grants
- $5.1M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | $198,790 | |
| Federal grant | Department of Health and Human Services · Phase I · Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825 | $507,284 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease | $304,787 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | $1,441,757 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | $1,449,910 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease | $1,244,790 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3011 | BACSTITCH DNA INC. | — | — |
| 3012 | Aincobio LLC | — | — |
| 3013 | VORTEX BIOTECHNOLOGY CORPORATION | — | — |
| 3014 | CIRCUMVENT PHARMACEUTICALS, INC. | — | — |
| 3015 | Recodagen LLC | — | — |
| 3016 | DeepMind | — | — |
| 3017 | MAA Laboratories Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.